회사 개요
Owlet, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry by delivering digital parenting solutions to parents in the United States, the United Kingdom, and international markets. The company's core business involves providing a digital parenting platform that offers real-time data and insights, alongside wearable infant health monitors such as the Dream Sock. Owlet, Inc. currently maintains a market capitalization of $145.03M and employs 108 individuals to support its operations. With annual revenue reaching $105.71M, these financial figures indicate that the company has achieved significant scale within the medical device space, yet the market cap reflects a valuation that is heavily influenced by future growth expectations rather than current profitability.
재무 건전성
Owlet, Inc. reported a trailing twelve-month revenue of $105.71M, which contrasts sharply with a net income of -$41,855,000 and an EBITDA of -$8,059,000. The substantial gap between the positive revenue of $105.71M and the negative net income of -$41.855M reveals a cost structure characterized by high operating expenses or significant losses on investments that exceed the company's gross profitability. The company generated a free cash flow of -$12,104,375, which indicates a lack of current financial flexibility as the business is burning cash rather than generating liquidity from its core operations. Profitability analysis shows a gross margin of 50.6%, suggesting efficient production costs, but this is offset by an operating margin of -18.4% and a profit margin of -37.5%, highlighting severe inefficiencies in covering overhead and administrative expenses relative to sales. Regarding liquidity, Owlet, Inc. holds $35.46M in cash against $13.12M in debt, resulting in a debt-to-equity ratio of 42.26, which suggests the balance sheet is leveraged relative to equity but retains a significant cash buffer. The current ratio stands at 1.85, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities with a comfortable margin. Furthermore, the return on equity is recorded at -802.5% and the return on assets at -7.6%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized in the asset base.
밸류에이션 평가
Valuation metrics for Owlet, Inc. present a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 51.50, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio is 7.28, which indicates that the market is valuing the company at a significant premium over its book value, likely driven by growth potential in the digital health sector. Alternative valuation measures include a price-to-sales ratio of 1.37 and an EV/EBITDA of -16.71, suggesting that investors are willing to pay a premium for revenue despite the negative earnings multiple. The stock has traded between a 52-week high of $16.94 and a 52-week low of $3.08, meaning the current price sits in a wide range relative to this historical volatility. The beta value of 1.98 indicates that the stock is highly volatile and is expected to fluctuate nearly twice as much as the broader market, reflecting the high risk associated with early-stage medical device companies.
Growth & Income
Owlet, Inc. demonstrated a revenue growth year-over-year of 29.6%, whereas earnings growth is listed as N/A due to the company's net loss position, implying that top-line expansion is occurring without a corresponding increase in profitability. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, indicating that the firm chooses to retain all earnings to fund operations and growth initiatives rather than returning capital to shareholders. The overall growth and income profile is defined by strong top-line expansion of 29.6% combined with a complete absence of income distribution, reflecting a strategy focused on market penetration and product development in the competitive medical device industry.